BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home » Authors » Sergio Held

Sergio Held

Articles

ARTICLES

Latin America: Brazil's Anvisa presents regulatory updates to global stakeholders

Sep. 22, 2014
By Sergio Held

Brazilian universities seeking partners for tech transfer

Sep. 16, 2014
By Sergio Held
RIO DE JANEIRO – Difficult and often uncertain intellectual property protections may be a key barrier to the development of a stronger biotech sector in Brazil, but new efforts from government, industry and academia may be slowly smoothing the way, according to multiple discussions at last week's BIO Latin America conference.
Read More

Latin America: As nanotech strengthens in Brazil, Anvisa steps up surveillance

Sep. 15, 2014
By Sergio Held

PDPs strengthen in Brazil as policy landscape renovation continues

Sep. 15, 2014
By Sergio Held
RIO DE JANEIRO – Product development partnerships (PDP) have become increasingly popular in Brazil, even as regulators work to establish clear rules and boundaries. The country has reported an increase of PDPs in the past few years, forcing regulators to deal with a number of issues including rules for technology transfers and finding a successful model for the public and private sectors to work together.
Read More

LatAm catches up with new regs, tech to become major biotech player

Sep. 12, 2014
By Sergio Held
RIO DE JANEIRO – Brazil is increasingly looking to put more resources into biotechnology, recognizing the great prospects. But it has to catch up in terms of technology and drug development.
Read More

Strategic incentivizing is a likely bet, but when will the payoffs start?

Sep. 11, 2014
By Sergio Held
RIO DE JANEIRO – Brazil's investments in science and technology have increased by more than 550 percent over the last decade, thanks in large part to a series of innovative programs to reward entrepreneurs and leverage the best research.
Read More

Latin America biotech markets still behind, working to catch up

Sep. 4, 2014
By Sergio Held
BOGOTA, Colombia – Multinational companies have stepped up their hunt for partners in Latin America as they seek to grow their businesses while promoting research in a region that has somehow fallen behind in both areas.
Read More

Latin America: Colombia's health minister reports price control for medical devices

Sep. 3, 2014
By Sergio Held

Colombian girls claim health problems after HPV vaccinations

Aug. 28, 2014
By Sergio Held
BOGOTA, Colombia – A community in Colombia is increasingly afraid of a human papillomavirus (HPV) vaccine after about 100 girls started showing a range of symptoms from headaches to fainting and numbness.
Read More

Latin America: Covidien premieres new $25 million physician training center in Brazil

Aug. 26, 2014
By Sergio Held
View All Articles by Sergio Held

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing